Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | F2 | P00734 | 4/20 | 0.41 |
| ▸ | PRSS1 | P07477 | 4/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 4/20 | 0.41 |
| ▸ | PRSS3 | P35030 | 4/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3486714 | 1.00 | POLB (0.45) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL3486084 | 0.90 | POLB (0.47) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL13498732 | 0.90 | POLB (0.47) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL3486085 | 0.90 | POLB (0.47) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL1321460 | 0.85 | POLB (0.45) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL12119821 | 0.85 | POLB (0.45) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL1302993 | 0.85 | POLB (0.45) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL1321457 | 0.85 | POLB (0.45) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL3451435 | 0.85 | POLB (0.45) | POLBPKMF2PRSS1PRSS2 | |
| SCHEMBL3485753 | 0.85 | PKM (0.56) | POLBPKMF2PRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMTED (JP) | 2010-02-04 | — | — | US | disclosed |
| EP-2058309-A1 | FUSED HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2009-05-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029619-A1 | FUSED HETEROCYCLIC COMPOUND | IRAK1, IL1R1, IRAK2 | POLB 4619/4885PKM 1216/4885F2 3370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.